• 1
    Huggins C, Hodges CV. Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 2937.
  • 2
    Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989; 321: 41924.
  • 3
    McLeod DG, Vogelzang NJ. Androgen blockade: monotherapy and quality-of-life issues. In: VogelzangNJ, ScardinoPT, ShipleyWU, CoffeyDS (eds). Comprehensive Textbook of Genitourinary Oncology, 2nd edn. Lippincott, Williams & Wilkins, Philadelphia, Pa, 2000; 82434.
  • 4
    Voda AM, Feldman BM, Grondeth E. Description of the hot flash: sensations, meaning and change in frequency across time. In: NotelovitzM, KeepPV (eds). The Climacteric in Perspective: Proceedings of the Fourth International Congress on the Menopause. MTP Press Limited, Lancaster, UK, 1986; 25969.
  • 5
    Charig CR, Rundle JS. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 1989; 33: 1758.
  • 6
    Kouriefs C, Georgiou M, Ravi R. Hot flushes and prostate cancer: pathogenesis and treatment. Br. J. Urol. Int. 2002; 89: 37983.
  • 7
    Miller JI, Ahmann FR. Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer. Urology 1992; 40: 499502.
  • 8
    Gerber GS, Zagaja GP, Ray PS et al. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000; 55: 97101.
  • 9
    Eaton AC, McGuire N. Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial. Lancet 1983; 2: 13367.
  • 10
    Moyad MA. Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women. Urology 2002; 59: 2033.
  • 11
    Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 9208.
  • 12
    Japanese Urological Association and the Japanese Pathological Society. General Rule for Clinical and Pathological Studies on Prostatic Cancer, 3rd edn. Kanehara, Tokyo, 2001; 957.
  • 13
    Loprinzi CL, Michalak JC, Quella SK et al. Megestrol acetate for the prevention of hot flashes. N. Engl. J. Med. 1994; 331: 34752.
  • 14
    Fossa SD, Aaronson NK, Newling D et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. Eur. J. Cancer 1990; 26: 11336.
  • 15
    Cassileth BR, Soloway MS, Vogelzang NJ et al. Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group. Qual. Life Res. 1992; 1: 3239.
  • 16
    Litwin MS, Hays RD, Fink A et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med. Care 1998; 36: 100212.
  • 17
    Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J. Pain Symptom Manage. 2001; 22: 97989.
  • 18
    Spetz AC, Hammar M, Lindberg B et al. Scandinavian Prostatic Cancer Group-5 Trial Study. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen deprivation for metastatic carcinoma of the prostate. J. Urol. 2001; 166: 51720.
  • 19
    Suzuki K, Kobayashi M, Tokue A. Clinical evaluation of hot flushes developing during endocrine therapy for prostate carcinoma. Jpn J. Urol. 2003; 94: 61420.
  • 20
    Berendsen HH. The role of serotonin in hot flushes. Maturitas 2000; 36: 15564.
  • 21
    Loprinzi CL, Pisansky TM, Fonseca R et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J. Clin. Oncol. 1998; 16: 237781.
  • 22
    Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356: 205963.
  • 23
    Stearns V, Isaacs C, Rowland J et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann. Oncol. 2000; 11: 1722.
  • 24
    Quella SK, Loprinzi CL, Sloan J et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen deprivation therapy for prostate cancer. J. Urol. 1999; 162: 98102.
  • 25
    Sartor O, Eastham JA. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med. J. 1999; 92: 41516.
  • 26
    Burch PA, Loprinzi CL. Prostate-specific antigen decline after withdrawal of low-dose megestral acetate. J. Clin. Oncol. 2001; 13: 10878.
  • 27
    Kelly WK, Scher HI. Prostate-specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J. Urol. 1993; 149: 607609.
  • 28
    Nishiyama T, Terunuma M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int. J. Urol. 1998; 5: 447.